الفهرس 
Epidemiology and Risk FactorsOnly 14 pages are availabe for public view
 |  | from | 171 |  |  |
| | | from | 171 | | |
Abstract
Lung cancer has been the most common cancer overall for several decades. According to the last data of GLOBOCAN series of the International Agency for Research on Cancer there were estimated 1.8 million new cases in 2012 of which 1.2 million cases estimated to occur in males with lower incidence rate in females about 583,000 cases (Ferlay et al., 2013).
Twenty seven percent of deaths from cancer in the United States in 2015 and 20% of deaths from cancer in the Europe in 2016 were related to lung cancer (Malhotra et al., 2016).
Egypt was completely lacking incidence rates at national level till the national population based cancer registry program was offered. Lung cancer occupied third or fourth rank representing 5-7%of cancers (Hussein et al., 2014).
More than sixty percent of diagnosed lung cancer cases occur at the age of 65 or older. Less than two percent of cases occur in people under the age of 45 years. The average age of lung cancer diagnosis is at the age of 70 (Malvezzi et al., 2013).
This study aims to ascertain retrospectively the epidemiology and prognostic factors of SCLC and also highlights the outcomes in the terms of overall survival (OS) and progression free survival (PFS) among Egyptian patients at clinical oncology and nuclear medicine department, Ain Shams university hospitals.
The median patient’s age was 62 years ( range from 42 to 84 years).Thirty five patients in the study were males while only 4 patients were females.
Among the 39 patient in the study, 32 patients received primary treatment, while 2 patients received only WCI as palliative intent, 2 patients received best supportive care treatment and 3 patients didn’t receive treatment as they lost follow up.
The response to treatment , 11 patients(34.4%) acheived PR, while 9 patients(28.1%) acheived PD, 2 patients acheived CR(6.3%) and only 1 patient(3.1%) acheived SD. Unknown response was found in 9 patients(28.1%) as they lost follow up.
For the 32 patients the estimated median progression free survival (PFS) was 10.6 months and the estimated mean was 10.4 months (95% confidence interval: 7.92-13.05).
For the 39 patients (whole group), the estimated median OS 11.17 (95%CI: 4.3-18) and the estimated mean was 14.5 months (95% CI: 11.3-17.6).
The median PFS was better in patients with ECOG 1 (95% confidence interval 6.1-16.1) with a significant P value 0.045.
The median PFS was better in patients with limited disease than those who are extensive (95% confidence interval 9.6-22.8) with a significant P value 0.005.
The mean OS was better in patients with ECOG1 and limited stage (95% confidence interval 13.1-20.4) (95% confidence interval 14.8-23.2) with significant P value 0.010 and 0.022 respectively, meanwhile the median was not reached due to censored data.
No great improvement in survival over the past years, so, health care centres should monitor the efficacy of their management plans by comparing survival outcomes with other centres.
Prognostic factors are essential in better understanding the treatment outcome in terms of OS and PFS.